Pembrolizumab (Keytruda, MSD) is indicated for 'the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option'.
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
The list price is £2,630 per 100-mg vial (excluding VAT; BNF online accessed January 2024).
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.